TransCode Therapeutics (RNAZ) Announces 1:33 Reverse Share Split
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/10/2026
- Wall St muted as markets monitor Hormuz situation; data awaited
- JPMorgan lifts S&P 500 target to 8,000 on strong earnings
- Jefferies cuts Apple rating as higher-priced iPhone roadmap looks difficult
- Oil rises 3% as Iran tempers hopes of Hormuz reopening
- Intel stock stumbles following blockbuster $15 billion equity offering
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
TransCode Therapeutics Announces 1-for-33 Reverse Stock Split
November 25, 2024 7:00 AM ESTSplit designed to achieve compliance with Nasdaq minimum bid price requirements
BOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (TransCode or the Company), the RNA Oncology Company committed to more effectively treating cancer using RNA therapeutics, today announced that its Board of Directors has approved a 1-for-33 reverse stock split. The reverse stock split was approved by TransCodes stockholders on November 22, 2024, and is intended to increase the per share trading price of the Company's common stock to enable the Company to satisfy the minimum bid price requirement for... More
